Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

  • Jesús San-Miguel
  • , Joan Bladé
  • , Ofer Shpilberg
  • , Sebastian Grosicki
  • , Frédéric Maloisel
  • , Chang Ki Min
  • , Marta Polo Zarzuela
  • , Tadeusz Robak
  • , Sripada V.S.S. Prasad
  • , Yeow Tee Goh
  • , Jacob Laubach
  • , Andrew Spencer
  • , María Victoria Mateos
  • , Antonio Palumbo
  • , Tom Puchalski
  • , Manjula Reddy
  • , Clarissa Uhlar
  • , Xiang Qin
  • , Helgi Van De Velde
  • , Hong Xie
    • Robert Z. Orlowski

Research output: Contribution to journal › Article › peer-review

128 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology